Drug Trial Radar · NCT07739888
Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
2,500
Planned (sponsor's estimate)
Start
Dec 30, 2027
Primary completion
Dec 30, 2030
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This OLE part is an optional, single arm, multicenter, open-label extension (OLE) added to the core part to assess the long-term safety, tolerability, the incidence of ischemic stroke or SE and bleeding events of abelacimab in eligible patients who completed the double-blinded core part of CMAA868A2302 (ANT-010/NCT05712200)
Conditions
- Atrial Fibrillation (AF)
Interventions
AbelacimabBiological
Abelacimab provided as liquid in vial (150 mg/mL)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first ISTH major Bleeding eventsTime frame: Up to 3 years
- Time to first BARC type 3c/5 bleedingTime frame: Up to 3 years
- Number of participants with ISTH major or CRNM bleedingTime frame: Up to 3 years
- Number of participants with bleedingTime frame: Up to 3 years
- Number of participants with TEAEs and TESAEsTime frame: Up to 3 years
- Number of participants with treatment discontinuations due to TEAEsTime frame: Up to 3 years
- Number of participants with device related AEs, SAEs, and device deficienciesTime frame: Up to 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.